157 related articles for article (PubMed ID: 24492032)
1. [Myelodysplastic syndromes: treatment strategy up-to-date].
Tohyama K
Rinsho Ketsueki; 2014 Jan; 55(1):12-21. PubMed ID: 24492032
[No Abstract] [Full Text] [Related]
2. Risk-based management of myelodysplastic syndrome.
Steensma DP; Tefferi A
Oncology (Williston Park); 2007 Jan; 21(1):43-54; discussion 57-8, 62. PubMed ID: 17313156
[TBL] [Abstract][Full Text] [Related]
3. [MDS].
Miyazaki Y
Rinsho Ketsueki; 2012 Jan; 53(1):51-8. PubMed ID: 22374525
[No Abstract] [Full Text] [Related]
4. Management of myelodysplastic syndromes: 2008 update.
Scott BL; Estey E
Oncology (Williston Park); 2008 Nov; 22(12):1344-52. PubMed ID: 19086598
[TBL] [Abstract][Full Text] [Related]
5. [Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
Moreno de Gusmão B; Guinea de Castro JM; Perez-Persona E; Oiartzabal I
Med Clin (Barc); 2014 Jan; 142(2):91-2. PubMed ID: 23790532
[No Abstract] [Full Text] [Related]
6. Is survival enough for myelodysplastic syndromes?
Santini V
Leuk Res; 2009 Aug; 33(8):1017-8. PubMed ID: 19268362
[No Abstract] [Full Text] [Related]
7. [Novel therapeutic agents for myelodysplastic syndrome].
Ishikawa T
Rinsho Ketsueki; 2009 Oct; 50(10):1553-9. PubMed ID: 19915366
[No Abstract] [Full Text] [Related]
8. [Treatment of acquired a plastic anemia: an update].
Kojima S
Rinsho Ketsueki; 2004 Mar; 45(3):202-8. PubMed ID: 15103933
[No Abstract] [Full Text] [Related]
9. How I treat patients with myelodysplastic syndromes.
Stone RM
Blood; 2009 Jun; 113(25):6296-303. PubMed ID: 19383969
[No Abstract] [Full Text] [Related]
10. [Treatment of MDS].
Usuki K
Rinsho Ketsueki; 2014 Oct; 55(10):1882-92. PubMed ID: 25297752
[No Abstract] [Full Text] [Related]
11. Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society.
Meers S; Breems D; Bries G; Delforge M; Graux C; Ravoet C; Selleslag D; Noens L;
Acta Clin Belg; 2013; 68(4):253-62. PubMed ID: 24455794
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes: biology and treatment.
Jädersten M; Hellström-Lindberg E
J Intern Med; 2009 Mar; 265(3):307-28. PubMed ID: 19141095
[TBL] [Abstract][Full Text] [Related]
13. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
Martin MG; Uy GL; Procknow E; Stockerl-Goldstein K; Cashen A; Westervelt P; Abboud CN; Augustin K; Luo J; DiPersio JF; Vij R
Bone Marrow Transplant; 2009 Jul; 44(1):13-7. PubMed ID: 19139740
[TBL] [Abstract][Full Text] [Related]
14. Impact on survival of different treatments for myelodysplastic syndromes (MDS).
Nachtkamp K; Kündgen A; Strupp C; Giagounidis A; Kobbe G; Gattermann N; Haas R; Germing U
Leuk Res; 2009 Aug; 33(8):1024-8. PubMed ID: 19185917
[TBL] [Abstract][Full Text] [Related]
15. Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Gao L; Gao L; Gong Y; Zhang C; Chen XH; Zhang X
Leuk Res; 2013 Nov; 37(11):1482-7. PubMed ID: 24054720
[TBL] [Abstract][Full Text] [Related]
16. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
Greenberg PL; Koller CA; Cabantchik ZI; Warsi G; Glynos T; Paley C; Schiffer C
Leuk Res; 2010 Dec; 34(12):1560-5. PubMed ID: 20615548
[TBL] [Abstract][Full Text] [Related]
17. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Milligan DW; Wheatley K; Burnett AK
Br J Haematol; 2004 Oct; 127(2):238-9. PubMed ID: 15461640
[No Abstract] [Full Text] [Related]
19. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
20. Iron chelation therapy for myelodysplastic syndrome: if and when.
Tefferi A
Mayo Clin Proc; 2006 Feb; 81(2):197-8. PubMed ID: 16471074
[No Abstract] [Full Text] [Related]
[Next] [New Search]
